# Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

> **NCT05312697** · PHASE2 · TERMINATED · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 2 (actual)

## Conditions studied

- Osteogenesis Imperfecta

## Interventions

- **BIOLOGICAL:** Setrusumab

## Key facts

- **NCT ID:** NCT05312697
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-28
- **Primary completion:** 2022-07-07
- **Final completion:** 2022-07-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Sponsor decision not related to safety concerns
- **Last updated:** 2025-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05312697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05312697, "Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05312697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*